or who fail to respond to initial measures. However, up to currently accepted therapy, including oxygen, ␤-agonists, and corti-30% of patients who present with acute asthma will fail to costeroids. Leukotriene receptor antagonists such as montelukast respond adequately to short-acting ␤-agonists (10), and benehave demonstrated efficacy in chronic asthma, but their efficacy in fit from systemic corticosteroids is not generally observed for acute asthma is unknown. In this randomized, double-blind, paral-4-6 hours or longer (11). As a result, current therapeutic lel-group pilot study, adults with moderate to severe acute asthma options for acute asthma do not adequately address treatment received standard therapy plus either intravenous montelukast (7 goals for a substantial number of patients. asthma. We hypothesized that in adult patients with acute adverse experiences were observed. We conclude that intravenous montelukast in addition to standard therapy causes rapid benefit asthma, the addition of montelukast to standard therapy and is well tolerated in adults with acute asthma.
quirement for prolonged or additional antiasthma therapy.
tion

METHODS
Acute asthma consistently ranks among the most frequent causes of emergency department visits in children and adults
Patients
and is a major contributor to time away from work, with Sixteen U.S. sites participated in this study, primarily emergency departan estimated two-million emergency department visits and ments that were affiliated with academic medical centers. Adults who 500,000 hospital admissions annually (1) (2) (3) (4) (5) . Furthermore, were 15-54 years old and who were presenting with acute asthma were acute asthma may account for a disproportionate share of screened for enrollment. For the purposes of this pilot study, patients direct asthma costs; in one study of asthma resource use, were required to have the following: a history of asthma for at least 1 hospitalizations accounted for 3.8% of total asthma encounyear, a history of tobacco use of less than 10 pack-years, and no concomitant therapy with systemic corticosteroids, leukotriene modifiers, antiters, but they comprised 44.6% of asthma costs (6) .
cholinergics, or long-acting ␤-agonist bronchodilators. Patients with Treatment goals for acute asthma include correction of pneumonia, congestive heart failure, or other clinical explanations for significant hypoxemia, rapid reversal of airflow obstruction, dyspnea were excluded, as were patients with significant comorbid and reduction in the likelihood of recurrent severe airflow disorders requiring acute management. The study protocol was apobstruction (7-9). Currently accepted initial therapy for acute proved by each investigator's respective institutional review board, and asthma includes oxygen and short-acting ␤-agonist bronchoall patients gave written informed consent to participate.
dilators; in addition, systemic corticosteroids should be considered for those patients who are severely ill at presentation
Study Design
This was a multicenter, double-blind (with in-house blinding procedures), randomized, placebo-controlled parallel group study consisting of a screening period and an active study period. The screening period (Received in original form August 5, 2002; accepted in final form October 30, 2002) began when the patient arrived at the study site and ended when the Supported by Merck and Co., Inc.
patient received study medication (maximum duration, 60 minutes). During the screening period and before consenting to the study, patients patients were excluded if the FEV 1 (expressed as a percentage of the included the proportion of patients receiving corticosteroids and the number of ␤-agonist treatments received during the active treatment predicted value) increased or decreased by greater than or equal to 20 percentage points between the two measurements. Patients who met
period. An additional analysis was performed on the number of patients who received more than two ␤-agonist treatments after intravenous the eligibility criteria were allocated by means of a blinded computergenerated randomization schedule with a blocking factor of six to readministration of the study drug. Percentages of treatment failures, percentages of patients receiving corticosteroids, and percentages of ceive study medication. Allocation numbers were encoded on labels included with the study drug, and patients were assigned the next patients receiving two or more ␤-agonists were compared using Fisher's exact test. A logistic model was also used to compare the percentage available allocation number in sequence at each site. Patients, investigators, and the in-house research team were not aware of actual treatment of treatment failures, the model including baseline FEV 1 and patient characteristics as covariates. The average number of doses of ␤-agonist allocations at any point during the study. The allocation code was not broken until after the study was completed and the dataset was declared administered per patient while in the emergency department was compared between the treatment groups using a nonparametric analysis of final.
Two doses of intravenous montelukast (7 and 14 mg; Merck and variance. All analyses followed the intention-to-treat approach. All patients with at least one prerandomization and at least one treatment Co., Inc., Whitehouse Station, NJ) were evaluated. Previous studies have shown that 7-mg intravenous montelukast yielded a single dose, plasma FEV 1 measure were included in the FEV 1 analyses. In the analysis of the average percentage changes from baseline in FEV 1 , if data at a concentration area under the curve (AUC) profile comparable to the approved 10-mg oral montelukast tablet (16) . Although there has been time point were missing, no value was carried forward. In the analysis of percent changes from baseline in FEV 1 at the different time points no additional clinical efficacy in chronic asthma evident at oral montelukast doses above 10 mg (17), in this study, the 14-mg dose of montelukast (10, 20, 40, 60 , and 120 minutes), if any FEV 1 measurement was not available within the time interval (0, 120 minutes), then the last available was included in addition to 7 mg to demonstrate that dose-related post-treatment measurement before the missing value was used instead. efficacy did not occur in acute asthma.
Based on the results of a previous study (13), a sample size of Intravenous montelukast (7 or 14 mg) or exact matching placebo 195 patients (130 receiving intravenous montelukast and 65 receiving was supplied as a lyophilized powder together with diluent (3.3% dexplacebo) gave 80% power to detect an 11 percentage point difference trose/0.3% normal saline). The study drug was reconstituted by a qualion the primary endpoint (the average percentage change in FEV 1 from fied individual not otherwise involved with the care of the patient and preallocation baseline) between the pooled montelukast groups and was administered as a manual bolus over 5 minutes. Serial spirometries placebo, assuming a SD of 25 percentage points. were performed at 10, 20, 40, 60, and 120 minutes and at 3 and 6 hours after intravenous study drug infusion. After the 20-minute spirometry, patients who were deemed eligible for discharge, who were admitted
RESULTS
to the hospital, or who withdrew from the study were not required to A total of 274 patients were screened for enrollment, and 201 perform the subsequent measurements. Corticosteroids and additional were randomized to receive study medication. A summary flow short-acting ␤-agonists were given as needed after the 20-minute spirometry. When indicated, corticosteroids were administered as a standiagram of patients enrolled in the study is depicted in Figure 1 . dard dose (prednisone, 60 mg orally).
The major reason for exclusion was failure to meet spirometric All patients successfully discharged from the emergency setting were criteria (57 of 73 patients [78%]). Of these, 49 were excluded given a standard course of oral prednisone (50 mg/day ϫ 5 days) and because of an FEV 1 of more than 70% of the predicted value were scheduled for a follow-up visit 14 Ϯ 3 days later. This standardized (before or after albuterol), whereas eight were excluded because outpatient course of prednisone was not counted when accounting for of an increase in FEV 1 (expressed as percent predicted value) of concomitant corticosteroids received during the active treatment pemore than 20 percentage points after an albuterol nebulization.
riod.
Baseline characteristics of randomized patients are presented in Table 1 . The treatment groups were comparable with respect Urinary Leukotriene E4 Measurements to age, sex, smoking history, age at asthma diagnosis, history of Urine samples were obtained during the acute treatment period and in atopy, and other clinical characteristics associated with asthma.
addition at a follow-up visit 2 weeks later for those patients successfully Most patients allocated in the study had moderate to severe discharged from the study site. Urinary leukotriene E4 (LTE 4 ) was asthma exacerbations (FEV 1 of less than 50-60% of the predicted analyzed by reversed-phase liquid chromatography after precolumn extraction combined with radioimmunoassay as described elsewhere value) (19). Initial FEV 1 (generally determined after one albut- (18) . Results were normalized to the creatinine concentration detererol treatments, according to the study design) was 39.2 Ϯ 14.2% mined in the same sample.
of the predicted value in the pooled montelukast groups and 46.4 Ϯ 15.4% in the placebo group. The mean preallocation FEV 1
Evaluations and Statistical Analyses
(determined immediately before study drug administration) was
The primary endpoint of the study was the average percentage change in 1.6 L, corresponding to 47% of the predicted value. The mean FEV 1 from preallocation baseline at 20 minutes after study medication preallocation FEV 1 was similar between patients receiving moninfusion. The preallocation baseline FEV 1 was defined as the FEV 1 , telukast and placebo (1.6 Ϯ 0.6 versus 1.7 Ϯ 0.6 L, respectively).
which immediately preceded randomization and study drug administraSeven patients (two in the montelukast 7-mg group, three in tion (i.e., the second spirometry in the screening period described prethe montelukast 14-mg group, and two in the placebo group) viously here). The analytic plan called for the pooling of the 7-and did not have valid FEV 1 data for the 10-and 20-minute time 14-mg montelukast treatment group results if no between-dose differpoints and were not included in the primary endpoint analyses.
ences on the primary endpoint were found. All FEV 1 analyses were Three patients (one from each of the three treatment groups) performed using an analysis of covariance model, with baseline FEV 1 as covariate, and significance was imparted at the p р 0.05 level. Shawere discontinued from the study for protocol violations after piro-Wilk test statistics were used to test for normality. Levene's test having received study drug (two due to discovery of concomitant was used to test for homogeneity of variances. Secondary endpoints medications taken before enrollment and one due to misinterincluded the proportion of patients in each treatment group who were pretation of baseline spirometry). However, these patients did determined to be treatment failures (defined as hospitalizations, need have valid data for the primary endpoint and were included in for an "excluded" medication, or need for greater than 6 hours of active the intention-to-treat analyses as prespecified in the protocol. bined with standard therapy, montelukast caused a significant improvement in FEV 1 was observed among patients receiving improvement in FEV 1 over the first 20 minutes after intravenous standard therapy plus intravenous montelukast at the earliest administration compared with that observed in patients receiving time point measured (10 minutes; mean percent change in placebo (the mean percentage change from preallocation base-FEV 1 ϭ 13.4% and 4.5% for pooled montelukast and placebo line, 14.8% versus 3.6% for the pooled montelukast and placebo groups, respectively; least square mean difference was 8.0%; treatment groups, respectively; least square mean difference was 95% confidence interval [CI], 0.9%, 15.1%; p ϭ 0.03). Moreover, 10%; 95% CI, 2.8%, 17.3%, p ϭ 0.007). These values were 19.5% this benefit was maintained for at least 2 hours; the least square and 5.2%, respectively, over the first 60 minutes (least square mean difference between the montelukast (pooled 7 and 14 mg mean difference of 13%; 95% CI, 5.2%, 20.7%; p р 0.001). doses) and placebo treatment groups at 2 hours was 14.1 percent- Figure 3 illustrates the distribution of FEV 1 responses (priage points with a 95% CI of 4.7%, 23.5% (p ϭ 0.003). mary endpoint) observed for patients receiving either monteluAs specified in the protocol, the primary endpoint was the kast or placebo. A similar unimodal pattern of responses was average percent change in FEV 1 from preallocation baseline observed for both groups, and there was no evidence of clearly defined "responders" and "nonresponders" to montelukast. over the first 20 minutes after study drug administration. Com- Least square means Ϯ SE responses in FEV 1 for montelukast (7-and 14-mg doses) and placebo. Patients received standard therapy plus either intravenous montelukast or placebo, and FEV 1 responses were determined at the indicated times after the end of the 5-minute infusion. Results are expressed as the percentage changes from preallocation baseline, which were 1.6, 1.6, and 1.7 L, respectively, for the montelukast 7-mg, montelukast 14-mg, and placebo groups, respectively. Montelukast at either dose caused a rapid improvement in FEV 1 compared with placebo. There were no differences between the montelukast treatment groups. † p Ͻ 0.05 for montelukast versus placebo; ‡ p Ͻ 0.01 for montelukast versus placebo.
Baseline factors, including demographics, asthma history, and dian ϭ 2.0; 95% CI, 1.5, 2.5; p ϭ 0.42 by analysis of variance). Expressed differently, compared with placebo, a smaller proporduration of symptoms before presentation, were examined in an attempt to identify predictors of response to treatment; other tion of patients in the montelukast group received two or more ␤-agonist treatments during the active treatment period (30.3% than treatment group and baseline FEV 1 , no factor was identified that explained the variability of the data (data not shown).
and 17.8%, respectively; 95% CI for difference, Ϫ28.5, 1.4; p ϭ 0.048 by Fisher's exact test; Figure 4 ). No other differences in We considered that any improvement in FEV 1 attributable to montelukast might be confounded by alterations in postranconcomitant therapy were observed between the groups. Using data from the pooled montelukast doses, a trend todomization concomitant therapy between the groups. In fact, patients randomized to intravenous montelukast at either dose ward a reduction in treatment failures was observed for montelukast versus placebo (11.1% versus 18.2%, respectively; 95% CI received corticosteroids less often than did those randomized to placebo (59.3% versus 75.8%, respectively; 95% CI for differfor difference, Ϫ22.6, 5.0; p ϭ 0.19 by Fisher's exact test; Figure 4 ). An exploratory analysis using a logistic model was ence, Ϫ31.5, Ϫ1.9; p ϭ 0.03; Figure 4 ). In addition, patients randomized to intravenous montelukast (either 7 or 14 mg) performed to study the influence of baseline factors on the probability of treatment failures. Other than treatment allocation, received numerically fewer ␤-agonist nebulizations (median ϭ 1.0; 95% CI, 0.8, 1.2) than those randomized to placebo (mebaseline FEV 1 was found to be a significant (p Ͻ 0.001) factor predicting the occurrence of treatment failure; no other such as treatment failures. Intravenous montelukast demonstrated a factors were identified. When baseline FEV 1 was considered in tolerability profile comparable to placebo, and no unexpected the analysis of treatment failures, the benefit for montelukast adverse experiences were noted. was significant (odds ratio compared with placebo ϭ 0.39; 95%
Although many asthma exacerbations are resolved promptly, CI, 0.15, 0.98; p ϭ 0.046). There was no difference between a substantial proportion (in particular patients presenting with patients receiving intravenous montelukast or placebo with remoderate to severe exacerbations) will require prolonged thergard to the frequency of unscheduled, asthma-related repeat apy in an acute setting and/or hospitalization. For example, up visits to the emergency room, hospitalizations, doctor visits, or to 30% of patients with acute asthma fail to respond adequately need for rescue corticosteroids in the 14-day period after disto short-acting ␤-agonists (10). Such patients typically receive charge from the study site (15 of 109 [13.8%] for montelukast, systemic corticosteroids, but benefit from systemic corticoste-6 of 49 [12.2%] for placebo, p ϭ NS).
roids is not generally observed for 4-6 hours or longer (11) . To explore the mechanisms underlying asthma exacerbations, Several studies have examined new interventions in acute urinary LTE 4 (a stable metabolite of leukotriene metabolism) asthma that could provide rapid and sustained relief from airflow was measured. Urinary LTE 4 levels were increased during the obstruction, in addition to current standard treatment. For examasthma exacerbations, as compared with levels obtained 2 weeks ple, inhaled ipratropium may provide a modest bronchodilator later (median 102.4 versus 69.5 pg/mg creatinine, respectively; benefit and an improvement in hospital admission rates, particup ϭ 0.009 by sign-rank test). There was no difference between larly in patients with severe asthma exacerbations (20-22), and treatment groups regarding this parameter. Although patients ipratropium is now used frequently for asthma in the acute setwith higher LTE 4 levels tended to have greater FEV 1 improveting (23). Others have suggested, however, that there is little if ments after montelukast, this did not reach statistical significance any added benefit of ipratropium above that of standard therapy (p ϭ 0.36).
with ␤-agonists (24) . Moreover, anticholinergics do not appear Thirty-three of the 201 randomized patients (16.4%) were to be effective for patients whose initial response to ␤-agonists discontinued from the study during the acute treatment period: is impaired (25), and at this point, there is no clear consensus 9 of 68 (13.2%) in the 7-mg intravenous montelukast group, 9 regarding their use (24, 26) . Other interventions for acute asthma of 67 (13.4%) in the 14-mg intravenous montelukast group, and that are current areas of active research include intravenous 15 of 66 (22.7%) in the placebo group. These differences were magnesium (27) , xanthines (28) , and inhaled helium/oxygen mixnot statistically different (p ϭ 0.11 for intravenous montelukast tures (29). versus placebo). Twenty-five of the 33 discontinuations (75.8%) Leukotriene pathways are activated in acute asthma, as eviwere due to clinical adverse experiences, of which 20 were hospidenced by elevations in urinary leukotriene excretion reported talizations for asthma (six, six, and eight in the 7-mg montelukast, elsewhere (30, 31) and confirmed in this study. The observations 14-mg montelukast, and placebo groups, respectively). In genthat corticosteroids do not inhibit leukotriene synthesis and actieral, intravenous montelukast was well tolerated, with an adverse vation and that the benefit of leukotriene modifiers is additive experience profile that was comparable to placebo. There were to corticosteroids, ␤-agonists, and theophylline in chronic asthma no unexpected adverse events. Two patients (one in the 14-mg provide a strong rationale for exploring the potential additive montelukast group and one in the placebo group) noted catheter benefit of leukotriene modifiers to current acute asthma treatsite discomfort during the study; in both cases, the symptoms ment. In a preliminary report, the addition of a high dose (160 mg) were mild and self-limited, and no specific action was taken with of oral zafirlukast to standardized therapy for acute asthma inregard to the study drug infusion.
cluding ␤-agonists and corticosteroids demonstrated a trend toward reduced adult hospital admissions from 15 to 10% (32) .
DISCUSSION
A potential limitation to any study that examines an adjunctive treatment is the definition of the standard therapy used In this study, intravenous montelukast compared with placebo as the comparison. In this study, standard therapy included oxywas associated with a rapid benefit as evidenced by a significant gen, ␤-agonist treatment, and at the investigator's discretion, improvement in FEV 1 within 10 minutes of administration. The systemic corticosteroids consistent with current treatment guidebenefit attributed to montelukast was not confounded by an lines (8, 9). Patients who were already receiving systemic corticoincreased use of ␤-agonists or corticosteroids and was accompanied by trends toward improvements in clinical outcomes such steroids and/or antileukotrienes before randomization were ex-
